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Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane
serine proteases. Previous studies indicated that TADG-15 is overexpressed in ovarian tumours; however, relationships between
expression of TADG-15 and clinical characteristics of ovarian cancer remain unclear. The purpose of this study was to examine
TADG-15 expression in ovarian cancers and determine any associations with clinicopathological characteristics or patient survival.
Immunohistochemical study revealed that TADG-15 was expressed in 50 (56.2%) of 89 ovarian carcinomas, whereas it was not
detected in normal ovaries. TADG-15 expression was significantly more common in patients with early stage disease compared with
patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P¼0.0157). Kaplan–
Meier survival curves demonstrated that patients with TADG-15-positive tumours have had substantially longer survival (P¼0.0480).
The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours
(P¼0.0053). Increased expression of TADG-15 is frequently detected in early stage cancers, with expression level downregulated
during progression of disease. TADG-15 is associated with early stage ovarian cancer and longer patient survival; therefore, it may be
a favourable prognostic marker for this malignancy.
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Proteases mediate specific proteolysis and contribute to numerous
biological processes, including embryo morphogenesis, tissue
rearrangement, complement activation, and blood coagulation
(Neurath, 1989). It is well documented that tumour progression
and invasion require the combined action of many proteolytic
enzymes such as metalloproteases and serine proteases (Mignatti
et al, 1986; Tryggvason et al, 1987; Liotta et al, 1991; Duffy, 1992).
These enzymes mediate the dissolution of extracellular matrix
components surrounding tumour cells, catalyse the degradation of
intercellular cohesive structures that allows shedding of tumour
cells into the extracellular environment, and activate growth and
angiogenic factors during tumour progression.
To assess the value of secreted proteases as markers for early
tumour detection and as targets for therapeutic intervention, we
developed a strategy to detect serine protease genes differentially
expressed in ovarian cancer using redundant primers to the
amino-acid sequences comprising the conserved catalytic triad
domain of the serine protease family (viz. His–Asp–Ser). Using
this approach, we have previously reported that several candidates
including hepsin, stratum corneum chymotryptic enzyme (SCCE/
KLK7), protease M (KLK6), TADG-12, and TADG-14 (KLK8) are
abundantly expressed in ovarian cancers (Tanimoto et al, 1997,
1999, 2001a; Underwood et al, 1999, 2000). In addition, we have
identified and cloned a novel serine protease tumour-associated
differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-
SP1) as reported in 1998 (Tanimoto et al, 1998).
TADG-15 is a transmembrane multidomain serine protease that
includes two CUB repeats (complement subcompliments C1r/C1s,
Uegf, and bone morphogenetic protein 1), four ligand binding
repeats of the low-density-lipoprotein receptor (LDLR) like
domain, and a serine protease domain in the extracellular space
(Tanimoto et al, 2001b). The total length of the cDNA is
approximately 3.15kb, and the nucleotide sequence includes a
single open reading frame for a protein of 855 amino acids. The
gene sequence was also identified as ST14 through subtractive
hybridisation analysis by Zhang et al (1998). Takeuchi et al (1999)
identified a sequence called MT-SP1 from the human prostate
cancer cell line PC-3. MT-SP1 is almost 100% identical to the
TADG-15 sequence at the nucleotide and amino-acid levels. There
is one amino-acid difference at the protein level, which is most
likely due to a sequencing error. Lin et al (1999) have described the
cloning of a matrix-degrading serine protease named matriptase,
which also appears to be homologous to TADG-15 with a structure
and homology to TADG-15 in the CUB, LDLR-L, and protease
domains. Matriptase was initially isolated from breast cancer cells
as an 80-kDa enzyme with gelatinolytic activity (Shi et al, 1993).
Subsequently, Lin et al (1999) revised their sequence to include a
cytoplasmic domain, a transmembrane domain, and an extra-
cellular domain upstream from the CUB, LDLR-L, and protease
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sdomains described for TADG-15. In addition, Kim et al (1999)
cloned a mouse transmembrane protease named epithin. Epithin
and TADG-15 are 84% similar over 855 amino acids, which
suggests that TADG-15 may be the human orthologue of this
mouse protein.
Recently, several membrane-anchored proteins sharing a num-
ber of common structural features including a proteolytic domain,
a transmembrane domain, a short cytoplasmic domain, and a
variable length stem region containing modular structural domains
were described as a new subfamily of serine proteases – the type II
transmembrane serine proteases (TTSPs) (Hooper et al, 2001). The
majority of TTSPs appear to be implicated in tumour growth,
progression, and metastasis. TADG-15 (ST14/matriptase/MT-SP1)
shares these common structural features of the TTSPs. Analyses of
the substrate specificity of TADG-15 (ST14/matriptase/MT-SP1)
reveal that the enzyme cleaves and activates the hepatocyte growth
factor/scattering factor and urokinase plasminogen activator (Lee
et al, 2000; Takeuchi et al, 2000). These substrate proteins are
known to play important roles in tumour development.
In the present study, we tested the hypothesis that TADG-15
may have prognostic value as an ovarian cancer biomarker by
investigating the expression of TADG-15 with immunohistochem-
ical techniques in ovarian carcinomas of different stages, grades,
and histological types; moreover, we correlated TADG-15 expres-
sion with clinicopathological parameters and patients’ survival
with the use of statistical analyses. In addition, to validate the
mRNA expression level, we examined TADG-15 mRNA expression
with semiquantitative PCR.
MATERIALS AND METHODS
Patients and tissue specimens
Epithelial ovarian cancer specimens were obtained from 89
patients (mean age 51.3 years, range 23–80 years) who had been
treated surgically at the Department of Obstetrics and Gynecology,
Hiroshima University Hospital (Hiroshima, Japan) between 1988
and 1999. Normal ovaries were obtained from seven patients who
underwent surgery for benign gynaecologic disease. Informed
consent was obtained from each subject according to institutional
guidelines. The primary pathologic diagnoses for the cancer
patients were serous adenocarcinoma for 39 patients, mucinous
adenocarcinoma for 19 patients, endometrioid adenocarcinoma for
17 patients, and clear cell adenocarcinoma for 14 patients. Clinical
staging was determined according to the criteria of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO). Of the 89
patients, 33 patients had stage I disease, 11 had stage II, 41 had
stage III, and four had stage IV disease. All patients received
radical or optimal cytoreductive surgery as the first step in
treatment and underwent complete clinical staging based on the
final histological and cytological findings after surgery to exclude
the presence of occult metastatic disease. Stage Ia or Ib and grade 1
patients received no further treatment. Most of the patients who
had stage Ic, II, III, or IV disease were treated with postoperative
platinum-based chemotherapy. A total of 11 patients received
paclitaxel as well as platinum agents. In the follow-up care clinic
for ovarian cancer patients, the patients were seen every month in
the first year of follow-up, every 2 months in the second year, every
3 months in the third year, and every 6 months in the fourth and
the fifth year; 5 years or more after initial therapy, annual follow-
up care was continued. The mean follow-up period was 53.0
months (range 3.5–169.1 months). All specimens were fixed in
10% neutral-buffered formalin and embedded in paraffin for
immunohistochemistry.
For the semiquantitative PCR analysis, fresh surgical specimens
from 51 ovarian cancers were available. These materials were
obtained immediately following the surgical procedure and were
cut in half. One half of each specimen was processed for
histological examination to determine the percentage of tumour
cells (never lower than 80% of all cells in the sample), while the
other half was frozen in liquid nitrogen and stored at  801C prior
to mRNA isolation.
Immunohistochemistry
Formalin-fixed and paraffin-embedded sections, 4mm thick, were
cut and mounted on aminopropyltriethoxysilane-treated slides.
Slides were routinely deparaffinised with xylene and rehydrated
with a series of ethanol washes. Nonenzymatic antigen retrieval
was performed by processing with use of microwave heat
treatment in 0.01 M sodium citrate buffer (pH 6.0). Immunohisto-
chemical staining was performed using the avidin–biotin perox-
idase complex technique (Vectastain Elite ABC kit, Vector
Laboratories, Burlingame, CA, USA) according to a previously
described method with some modifications (Tanimoto et al,
2001b). Anti-TADG-15 rabbit polyclonal antibody was generated
by immunisation with a combination of 2-poly-lysine-linked
multiple Ag peptide derived from the TADG-15 protein sequence
as described previously (Tanimoto et al, 2001b). The final products
were visualised using the 3-amino-9-ethylcarbazole (AEC) sub-
strate system (DAKO Co., Carpinteria, CA, USA). Both positive
and negative controls were used for each section. Ovarian
carcinoma samples known to show positive TADG-15 staining
were used as positive controls according to published literature
(Tanimoto et al, 2001b). Normal rabbit serum IgG (Vector
Laboratories, Burlingame, CA, USA) was used as a negative
control in place of the primary antibody. All experiments were
duplicated. The percentage of positive tumour cells was scored as
follows. When no positive tumour cell stain could be identified or
when fewer than 10% of the focally distributed tumour cells were
positive, staining was considered negative. When more than 10%
of the tumour cells showed positive staining, staining was
considered positive. All stained slides were scored independently
by two of the authors (KS and XT).
Semiquantitative PCR
Extraction of mRNA from the tissue specimen and cDNA synthesis
were carried out by methods described previously (Shigemasa et al,
1997; Tanimoto et al, 1997, 2001b). The mRNA was isolated using a
RiboSepTM mRNA isolation kit (Becton Dickinson Labware,
Bedford, MA, USA). The cDNA was synthesised with 2.0mgo f
mRNA by random hexamer priming using the AdvantageTM RT-
for-PCR kit (Clontech, Palo Alto, CA, USA).
Expression levels of TADG-15 mRNA were examined by a
semiquantitative PCR technique with minor modifications to a
previously described method (Shigemasa et al, 1997; Tanimoto
et al, 1997, 2001b). The TADG-15 sense primer sequence was
50-ATGACAGAGGATTCAGGTAC-30 and the antisense primer
sequence was 50-GAAGGTGAAGTCATTGAAGA-30. The internal
control was b-tubulin. The b-tubulin sense primer was 50-TGCATT
GACAACGAGGC-30, and the antisense primer was 50-CTGTCTTG
ACATTGTTG-30. Reaction mixtures consisted of cDNA derived
from 50ng mRNA, 5pmol sense and antisense primers, 200mmol
dNTPs, and 0.625U Taq DNA polymerase with reaction buffer
(Takara Biochemicals, Kyoto, Japan) in a final volume of 25ml. A
total of 30 cycles of PCR were carried out in a Thermal Cycler
(Perkin Elmer, Foster City, CA, USA). Each cycle of PCR included
30s of denaturation at 941C, 60s of annealing at 601C, and 60s of
extension at 721C. We confirmed that amplification under these
conditions resulted in linear production of each product. PCR
products were separated on 2.0% agarose gels, and the density of
each PCR product was determined using a Printgraph-Densito-
graph system (ATTO Co., Tokyo, Japan). In the present study, we
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sused the expression ratio (TADG-15/b-tubulin) as measured by a
Printgraph-Densitograph system to evaluate gene expression.
Statistical analysis
For statistical analysis, the w
2-test of significance and the Fisher’s
exact test were used to analyse the distribution of TADG-15
expression in the cancer cases according to their clinicopatholo-
gical characteristics. A Kaplan–Meier survival curve of ovarian
cancer patients was prepared according to TADG-15 protein
expression status, with differences in overall survival rates
determined by the log-rank test. Overall survival time was defined
as the period between initial surgery and the time of death.
Survival times of patients who were still alive were noted along
with the date of the most recent follow-up appointment. For
multivariate analyses, we used the Cox proportional hazards
model. The unpaired T-test was used to assess the differences of
the mean value of the relative TADG-15 mRNA expression ratio
(TADG-15/b-tubulin) between groups. All P-values quoted are
two-sided with statistical significance defined as a P-value o0.05.
The Stat View 5 program (Abacus Concepts, Inc., Berkeley, CA,
USA) was used for statistical analysis.
RESULTS
Immunohistochemical analysis of TADG-15
Immunohistochemical expression of TADG-15 was examined in 89
epithelial ovarian carcinomas and seven normal ovaries. Figure 1
shows representative samples. Positive TADG-15 staining was
A B
C D
E
Figure 1 Immunohistochemistry. TADG-15 is absent in normal ovarian surface epithelial cells (A,  100). Positive TADG-15 staining is observed in
serous (B,  100), endometrioid (C,  100), and clear cell adenocarcinoma (D,  100). Negative control section showed no nonspecific staining (E, same
tumour as shown in D,  50).
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sobserved in both the cytoplasm and on the cell surface of ovarian
carcinoma cells, whereas normal ovarian surface epithelium
showed negative TADG-15 staining.
Of 89 ovarian carcinomas examined, 50 (56.2%) were positive
for TADG-15. Table 1 shows positive TADG-15 expression in
relation to each patient’s age, clinical stage, histological type, and
histological grade. TADG-15 was detected more frequently in stage
I cases than in cases of advanced stage disease (stage I, 24 of 33:
72.7%; stage II/III/IV, 26 of 56: 46.4%; P¼0.0157, w
2-test). In 33
stage I cancers, serous adenocarcinomas represent six cases,
mucinous adenocarcinomas 12 cases, endometrioid adenocarci-
nomas six cases, and clear cell carcinomas nine cases. When
expression was evaluated in relation to histological subtype, clear
cell adenocarcinomas (14 of 14, 100%) expressed TADG-15 more
frequently than serous (17 of 39, 43.6%), mucinous (10 of 19,
52.6%), or endometrioid adenocarcinomas (nine of 17, 52.9%). Out
of 14 TADG-15 positive clear cell cancers, nine cases were stage I
cancers. No significant correlation was found between positive
TADG-15 expression and patient age or tumour histological grade.
Survival analysis
Data from univariate and multivariate analysis on the influence of
age, clinical stage, histological grade, and TADG-15 expression
status on patient overall survival are summarised in Table 2. In
univariate analysis, log-rank testing revealed that older age,
advanced clinical stage, high histological grade, and negative
TADG-15 expression were significantly correlated with poor
patient overall survival (age, P¼0.0008; stage, Po0.0001; grade,
P¼0.0043; TADG-15, P¼0.0480). Ovarian cancer patients were
categorised along a Kaplan–Meier survival curve according to
negative vs positive expression of TADG-15, showing a statistically
significant association between negative TADG-15 expression and
poor patient overall survival (P¼0.0480, log-rank test, Figure 2).
In multivariate analysis, age (o50 years vs 451 years), clinical
stage (stage I vs stage II/III/IV), histological grade (grade 1 vs grade
2/3), and TADG-15 expression status (positive vs negative) were
selected as covariable. Clinical stage was identified as a significant
and independent variable (Po0.0001), whereas none of the other
variables were significantly associated with overall survival in
multivariate models.
Semiquantitative PCR analysis for TADG-15 mRNA
expression
In order to evaluate mRNA expression of TADG-15 in ovarian
carcinomas, we performed semiquantitative PCR. In a preliminary
study, the linearity of PCR amplification was confirmed. Figure 3
shows an example of semiquantitative PCR using TADG-15
primers coamplified with the internal control (b-tubulin) primers.
Analysis of data as measured using the densitograph system and
compared as ratios of expression (TADG-15/b-tubulin) indicated
that TADG-15 expression was significantly elevated in carcinomas
compared with that of normal ovaries (Po0.0001) (Table 3). For
individual clinical stages of tumours, the mean value of relative
TADG-15 mRNA expression ratio was 1.9870.57 (mean7s.d.) for
stage I tumours, 1.3770.08 for stage II tumours, 1.6470.34 for
stage III tumours, and 1.6970.31 for stage IV tumours,
respectively. The TADG-15 mRNA expression ratio was signifi- Table 1 Expression of TADG-15 in relationship to age, clinical stage,
histological type, and histological grade in patients with ovarian carcinomas
N TADG-15 positive for expression (%) P-value
a
Ovarian carcinoma 89 50 (56.2)
Patient age (years) 0.2776
o50 40 25 (62.5)
451 49 25 (51.0)
Clinical stage 0.0157*
Stage I 33 24 (72.7)
Stage II/III/IV 56 26 (46.4)
Histological type 0.0035*
Serous 39 17 (43.6)
Mucinous 19 10 (52.6)
Endometrioid 17 9 (52.9)
Clear cell 14 14 (100)
Histological grade 0.2442
Grade 1 54 33 (61.1)
Grade 2/3 35 17 (48.6)
aw
2-test. *Statistically significant.
Table 2 Univariate and multivariate analysis on the influence of age, clinical stage, histological grade, and TADG-15 expression status on overall survivali n
patients with ovarian cancer
Multivariate
b
Factors Univariate P-value
a RR
c 95% CI
d P-value
Patient age (o50 years vs 451 years) 0.0008 0.525 0.246–1.121 0.0959
Clinical stage (stage I vs stage II/III/IV) o0.0001 0.050 0.011–0.223 o0.0001
Histological grade (grade 1 vs grade 2/3) 0.0043 0.705 0.371–1.342 0.2872
TADG-15 expression (positive vs negative) 0.0480 1.097 0.577–2.087 0.7768
aLog-rank test.
bCox proportional hazard model.
cRR, risk ratio.
dCI, 95% confidence interval.
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Figure 2 Log-rank testing shows that positive TADG-15 expression is
significantly correlated with favourable overall survival in ovarian cancer
patients (negative vs positive TADG-15 expression, P¼0.0480).
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scantly higher in stage I tumours than in stage II/III/IV tumours
(P¼0.0053) (Table 3).
DISCUSSION
Recently, several studies have documented the enzymatic function
of TADG-15 (Takeuchi et al, 1999, 2000; Lee et al, 2000; Friedrich
et al, 2002). Analyses of the catalytic domain structure and the
substrate specificity of TADG-15 (ST14/matriptase/MT-SP1) reveal
that it has narrow substrate specificity; single-chain precursor of
hepatocyte growth factor (HGF)/scattering factor (SF), protease-
activated receptor 2 (PAR2) and single-chain urokinase plasmino-
gen activator (uPA) are known macromolecular substrates of this
protease (Lee et al, 2000; Takeuchi et al, 2000; Friedrich et al,
2002). These findings support the hypothesis that TADG-15 (ST14/
matriptase/MT-SP1) is involved in regulatory events that require
selective processing of particular substrates rather than nonselec-
tive degradation (Takeuchi et al, 1999). TADG-15 appears to play
an important role in the development of cancer through its
activation of some precursor proteins, of which active forms are
crucial for cellular proliferation, cell motility, angiogenesis, and
activation of other protease systems during tumour growth and
invasion.
In the present study, we examined the expression of TADG-15 in
ovarian cancer and its association with clinicopathological
parameters and patient survival. Of 89 ovarian carcinomas, 50
(56.2%) produced high levels of TADG-15 that were detected by
immunohistochemistry, whereas normal ovaries produced extre-
mely low levels of this protein. This differential expression of
TADG-15 between carcinoma and normal ovarian tissue was
confirmed by semiquantitative PCR. Relative expression levels of
TADG-15 mRNA from ovarian carcinomas were significantly
higher compared with those of normal ovaries. This differential
expression raises the possibility that TADG-15 might serve as a
biomarker for ovarian cancer.
Among clinicopathological parameters we examined, clinical
stage and histological type correlated with TADG-15 expression.
With regard to histological type, clear cell adenocarcinoma showed
TADG-15 expression more frequently than serous, mucinous, or
endometrioid adenocarcinoma. One possible explanation of this
difference among histological types is that there are alternative
pathways of proteolytic reactions in tumour progression, and the
pathway involving TADG-15 may correlate with some histological
phenotypes including clear cell adenocarcinoma of the ovary.
Oberst et al (2001) reported that TADG-15 expression was
observed in tumours of epithelial origin but not in stromal-
derived tumours and sarcomas. These findings support the
hypothesis that there may be alternative pathways of proteolytic
reactions correlating with histological type, cellular origin of
malignancy, or both. With regard to clinical stage, TADG-15
expression was significantly more frequent in patients with stage I
tumours than stage II/III/IV tumours. Furthermore, the mean
value of relative TADG-15 mRNA expression ratio was also
significantly higher in stage I tumours than in stage II/III/IV
tumours. These findings indicate that increased expression of
TADG-15 is mainly associated with early events in the develop-
ment of malignancy (reflected as early stage disease) and its
expression level is downregulated during cancer progression. This
expression pattern suggests that TADG-15 may be important in
establishing primary ovarian tumours and it later may function
directly or indirectly as a progression inhibitor. Oberst et al (2002)
investigated expression of TADG-15 (matriptase) and its inhibitor,
hepatocyte growth factor activator inhibitor-1 (HAI-1), in ovarian
cancer and reported that early stage tumours are more likely to
express TADG-15 (matriptase) than advanced stage tumours and
that TADG-15 (matriptase): HAI-1 ratio is increased in tumours of
more advanced stage. Although we did not examine the expression
of HAI-1 in the present study, our results also show that
expression of TADG-15 is significantly associated with early stage
ovarian cancer. Our results also demonstrate that patients with
TADG-15-positive tumours have longer survival according to
univariate analysis, although this statistical significance was lost in
multivariate modeling. While TADG-15 might not be an indepen-
dent prognostic factor for ovarian cancer, this protease is
significantly associated with early stage disease and longer patient
survival.
Previous studies have documented that some serine proteases
are downregulated in various human carcinomas. For example,
human kallikrein (KLK) 10 (normal epithelial cell specific-1; NES1)
and KLK 14 are reported to be downregulated in breast cancer
(Goyal et al, 1998; Yousef et al, 2001). Recently, Diamandis and
Yousef (2002) reviewed human kallikreins, a subgroup of the
serine protease family that colocalises at chromosomal region
19q13.4 and shares a high degree of homology. As described by
these authors, some kallikreins can be useful biomarkers for poor
prognosis of cancer, and others can be biomarkers for favourable
prognosis. These findings indicate that proteolytic enzymes
are not always associated with more aggressive forms of human
cancer, even if they might be located at the same chromosomal
region and share a high degree of homology. The process of
tumour progression and invasion is thought to be a complicated
phenomenon that involves a cascade of many kinds of proteases
(Mignatti et al, 1986; Tryggvason et al, 1987; Liotta et al, 1991;
Duffy, 1992). In this cascade, some proteases contribute to invasive
tumour behaviour, and some proteases mediate activation of
inhibitors of these proteases. Although the precise role of TADG-
15 in this cascade remains unclear, our results demonstrated that
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Figure 3 Semiquantitative PCR analysis of TADG-15 expression.
Expression levels of TADG-15 relative to b-tubulin are significantly
elevated in carcinomas compared with levels in normal ovaries.
Table 3 Relative expression levels of TADG-15 mRNA in normal
ovaries and ovarian carcinomas
Tissue type N TADG-15 (mean7s.d.)
a
Normal ovary 7 0.1970.19
b
Ovarian carcinoma 51 1.7670.47
b
Clinical stage of carcinoma
Stage I 21 1.9870.57
c
Stage II/III/IV 30 1.6170.32
c
as.d.¼standard deviation.
bNormal vs carcinoma; Po0.0001.
cStage I vs stage II/III/IV;
P¼0.0053. All P-values were calculated using an unpaired t-test.
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sincreased expression of TADG-15 is frequent, especially in early
stage ovarian cancer, which suggests that this enzyme may be
involved in the initial spread of disease. TADG-15 therefore may
serve as a marker for early detection of ovarian cancer.
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